Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | SLC6A5 | Q9Y345 | 8/20 | 0.59 |
| ▸ | SLC6A9 | P48067 | 8/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | WDR5 | P61964 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29536266 | 0.88 | ALDH1A1 (0.68) | MAPTTHRBALDH1A1LMNAPOLB | |
| SCHEMBL28702263 | 0.88 | MAPT (0.70) | MAPTTHRBALDH1A1LMNAPOLB | |
| SCHEMBL994347 | 0.88 | ALDH1A1 (0.68) | MAPTTHRBALDH1A1LMNAPOLB | |
| SCHEMBL6840537 | 0.86 | ALDH1A1 (0.53) | MAPTTHRBALDH1A1LMNAPOLB | |
| SCHEMBL30957484 | 0.86 | LMNA (0.69) | MAPTTHRBALDH1A1LMNAPOLB | |
| SCHEMBL3553731 | 0.86 | LMNA (0.69) | MAPTTHRBALDH1A1LMNAPOLB | |
| SCHEMBL1498664 | 0.84 | POLB (0.65) | MAPTTHRBALDH1A1LMNAPOLB | |
| SCHEMBL6495866 | 0.84 | ALDH1A1 (0.63) | MAPTTHRBALDH1A1LMNAPOLB | |
| SCHEMBL31639893 | 0.84 | ALDH1A1 (0.63) | MAPTTHRBALDH1A1LMNAPOLB | |
| SCHEMBL14464189 | 0.84 | ALDH1A1 (0.79) | MAPTTHRBALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2628481-B1 | Trisubstituted heterocycles as replication inhibitors of hepatitis C virus HCV | ABBVIE BAHAMAS LTD (BS) | 2016-02-24 | — | — | EP | disclosed |
| US-20150218194-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-9006387-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2853531-A2 | Antiviral compounds | AbbVie Bahamas Ltd. (BS) | 2015-04-01 | — | — | EP | disclosed |
| EP-2455376-B1 | Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) | ABBVIE BAHAMAS LTD (BS) | 2014-11-26 | — | — | EP | disclosed |
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES | 2014-10-23 | — | — | US | disclosed |
| EP-2337781-B1 | ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION | ABBVIE BAHAMAS LTD (BS) | 2014-07-23 | — | — | EP | disclosed |
| EP-2628481-A1 | Trisubstituted heterocycles as replication inhibitors of hepatitis C virus HCV | AbbVie Bahamas Ltd. (BS) | 2013-08-21 | — | — | EP | disclosed |
| EP-2455376-A1 | Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-2368890-A1 | Hepatitis C virus inhibitors | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2337781-A2 | ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION | Abbott Laboratories (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2010144646-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | MAPT 2833/4885THRB 4622/4885ALDH1A1 2858/4885 |
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | MAPT 2833/4885THRB 4622/4885ALDH1A1 2858/4885 |
| US-20150218194-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | MAPT 2833/4885THRB 4622/4885ALDH1A1 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.